Welcome to our dedicated page for Evolent Health news (Ticker: $EVH), a resource for investors and traders seeking the latest updates and insights on Evolent Health stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Evolent Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Evolent Health's position in the market.
Evolent Health, Inc. (NYSE: EVH) has announced a strategic partnership with digital cancer care platform Careology to enhance cancer care in the U.S. This collaboration aims to provide more coordinated, connected, and empowered journeys for individuals living with cancer. By integrating Careology's digital cancer care technology into Evolent's comprehensive care navigation services, the joint platform will offer personalized information, tools, and support to help patients manage their diagnoses and treatment regimens more effectively. The partnership comes at a important time as global cancer rates are expected to increase significantly, and the U.S. faces challenges such as rising costs and drug shortages in cancer care.
Evolent Health, Inc. announced strong first quarter results, with a revenue increase of 49.6% to $639.7 million and an Adjusted EBITDA of $54.1 million. The company raised its revenue outlook for full year 2024 and reiterated its Adjusted EBITDA guidance. Evolent also highlighted new revenue agreements and an exclusive partnership with Careology. Despite a net loss of $(25.2) million, the CEO remains optimistic about the company's growth potential.